FACT SHEET

Abbott’s Deep Brain Stimulation (DBS) system

Directional stimulation through DBS for the treatment of Parkinson’s disease and essential tremor

PARKINSON’S DISEASE AND ESSENTIAL TREMOR
Parkinson’s disease and essential tremor are neurologic conditions known as movement disorders which are caused by a communication breakdown throughout the central nervous system. This can result in a debilitating loss of muscle control, involuntary movement and reduced coordination. At present there are no proven cures for movement disorders. At present there are no proven cures for movement disorders. Treatment options focus on alleviating symptoms to improve quality of life. Essential tremor is often associated with or misdiagnosed as Parkinson’s disease but they differ in key ways, including the progression of the condition, timing of the tremors, and additional motor and non-motor symptoms.

DEEP BRAIN STIMULATION
Deep brain stimulation (DBS) is a surgical procedure to treat the motor symptoms of movement disorders such as Parkinson’s disease or essential tremor. Leads are implanted in a targeted area of the brain that controls movement. A battery-powered neurostimulator—similar in function and appearance to a cardiac pacemaker—is implanted under the skin and controls the amount of stimulation delivered by the leads. These “pacemakers for the brain” deliver electrical impulses to regulate or block abnormal motor impulses. DBS is now a standard of care therapy considered for patients whose motor symptoms are not adequately controlled by medications.

ABBOTT’S DBS INNOVATION
Prior to the latest Abbott approval, people new to DBS therapy or those living with older systems from other manufacturers may have experienced barriers in accessing the most advanced DBS therapy options because of the potential need for an MRI in the future. Abbott has addressed this challenge with the Infinity DBS system’s improved therapy platform—the first and only approved DBS platform in the United States to feature a MRI-ready system with directional lead. Abbott’s directional leads are designed to direct stimulation toward targeted areas of the brain to maximize patient outcomes and limit side effects. The platform’s future-ready technology is built with the ability to significantly upgrade the capabilities and new therapy features of the Infinity DBS system through simple, over-the-air updates.

PATIENT-CENTRIC THERAPY WITH APPLE TECHNOLOGY
Abbott’s Infinity DBS system is the world’s first and only DBS system operating on a Bluetooth iOS software platform using Apple technology. Clinicians can streamline the programming process with an iPad mini device using Abbott’s new Informity™ Programming Software to become more efficient in their practice and achieve optimal outcomes with directional leads. Patients can discreetly manage their symptoms with their Infinity DBS System iPod touch controller.

In addition to using familiar Apple technology, patients benefit from a recharge-free DBS device with the Infinity DBS system. This means people living with their Infinity DBS system do not need to be reminded of their condition and pause from their daily activities to charge their battery as with other systems.

Abbott’s Infinity DBS system is FDA and CE Mark approved and has been used in nearly 30 countries, most recently in the United States, Russia, Saudi Arabia and Taiwan. For U.S. important safety information, visit: https://abbo.tt/2JSxXBC.

Note: Apple, iPod touch and iPad mini are trademarks of Apple, Inc. Bluetooth is a registered trademark of Bluetooth SIG, Inc., iOS is a trademark of Cisco Technology, Inc.